Frostbite Mark Mitchell, Co-Founder & General Partner at Weave VC

We had a chance to sit down with our friend Chris Robson for a deep dive into startup fundraising. Chris is the CEO & Co-founder at Edmonton based Wyvern, a space data company enabling next-generation earth observation using hyper-spectral cameras.



If you're an entrepreneur thinking about that first raise, be sure to listen in as Chris shares some of his learnings after successfully raising $17.M in capital from some of North America's top seed investors including MaC Venture Capital, Uncork Capital, Y-Combinator, and Soma Capital.



We were fortunate enough to participate in Wyvern's early rounds of financing through our angel syndicate Red Thread Ventures and our venture capital firm Weave VC and have been amazed at their progress over the past few years!



For more information on Wyvern and their offerings, please visit them online at https://wyvern.space/

Today’s guest is Dr. Mads Daugaard. Mads is the Co-founder, President and Chief Scientific Officer at Canadian cancer therapeutics company, Rakovina Therapeutics, a Red Thread Ventures portfolio company. This is his third time on our podcast and in today’s session we focused on Rakovina’s 2022 progress, their partnership with the St.Baldrick's foundation, distinctions between first generation/next generation therapies, and their push to IND filing and human clinical trials. We hope you enjoy today’s discussion with Dr. Mads Daugaard!



Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies. The Company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory
agencies. Further information can be found at www.rakovinatherapeutics.com, on LinkedIn, and on Twitter @rakovina_rkv.



Red Thread Ventures has featured Rakovina in multiple blog posts, head over to www.redthread.ventures/blog to learn more.

Dr. Mads Daugaard is the Co-founder, President and Chief Scientific Officer at biotech company, Rakovina Therapeutics. Founded in 2020, Rakovina is striving to revolutionize cancer treatment and extend the lives of cancer patients. Not yet in human clinical trials, they are developing medicines that selectively target and kill cancer cells using leading-edge science that we’ll discuss with Mads in this episode. The therapeutics company has 3 research programs, Kt-2000, 3000 and 4000, all of which are in the preclinical stage of drug development. Rakovina is currently being traded on the TSX Venture Exchange under the symbol RKV.



On April 8th in New Orleans, Mads is attending the American Association for Cancer Research or AACR annual meeting, which is the largest cancer research conference.  Following that he is sharing an abstract highlighting Rakovina’s KT-3000 series at AACR’s special conference on Sarcoma cancer in Montreal. The episode highlights why it is so important for Rakovina and other preclinical biotech companies to attend conferences like these. 



To learn more about Rakovina's presentation at the AARC conference, you can view their press release here.

To continue your dive into biotech investing, check out this blog series featuring Rakovina: Myths and Risks in Biotech Investing



Rakovina Therapeutics

Website 

LinkedIn 

Twitter



Red Thread Ventures 

Website

LinkedIn 

Youtube

On today's episode, we sit down with Doctor Mads Daugaard, the President and Chief Scientific Officer at Rakovina Therapeutics. Mads is a molecular biologist who earned his PhD degree from the Faculty of Health Sciences, University of Copenhagen, for his studies on heat shock proteins in relation to cancer cell survival mechanisms. He is also Head of the Molecular Pathology and Cell Imaging Unit, Senior Research Scientist at Vancouver Prostate Centre, and associate Professor at Department of Urologic Sciences, University of British Columbia. 



Check out this episode to learn more about biotech industry, preclinical research, and the impressive waves that Rakovina Therapeutics are creating in the oncology space. 

On today's episode, we sit down with Mark Mitchell, the Principle and Director of Red Thread Ventures, the investment firm where we work; Mark is also the Co-Founder at IPEX. Mark has had the pleasure of travelling around the world and building connections, while simultaneously building up his portfolio of experiences. More specifically, he has immersed himself with business in China (he is even fluent in Mandarin too!). Through our conversation, we learn more about the benefits of conducting business internationally as well as the Dos and Don'ts of networking. Mark's tips apply to everyone, whether you are a student or a seasoned professional, so you won't want to miss it!

We have an expected guest for today's episode, Xin Zheng, otherwise known as Prof X to us. Prof X was our financial accounting professor this summer and is a passionate individual who was always sharing fun investing stories during class. During our discussion, we talk about what it means to be a fundamentals-based investor, his current hot stock and some advice to beginner investors. This episode is a personal favourite, and we hope you have fun and learn a lot!